Table of Content

1 Granulomatosis with Polyangiitis Drug Market Overview
1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Granulomatosis with Polyangiitis Drug Segment by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Type (2024-2034)
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Granulomatosis with Polyangiitis Drug Segment by Application
1.3.1 Global Granulomatosis with Polyangiitis Drug Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Granulomatosis with Polyangiitis Drug Market Size Estimates and Forecasts
1.4.1 Global Granulomatosis with Polyangiitis Drug Revenue 2018-2034
1.4.2 Global Granulomatosis with Polyangiitis Drug Sales 2018-2034
1.4.3 Global Granulomatosis with Polyangiitis Drug Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Granulomatosis with Polyangiitis Drug Market Competition by Manufacturers
2.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturers (2018-2024)
2.4 Global Granulomatosis with Polyangiitis Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Product Type & Application
2.7 Granulomatosis with Polyangiitis Drug Market Competitive Situation and Trends
2.7.1 Granulomatosis with Polyangiitis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Granulomatosis with Polyangiitis Drug Players Market Share by Revenue
2.7.3 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Granulomatosis with Polyangiitis Drug Retrospective Market Scenario by Region
3.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global Granulomatosis with Polyangiitis Drug Global Granulomatosis with Polyangiitis Drug Sales by Region: 2018-2034
3.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2018-2024
3.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2024-2034
3.3 Global Granulomatosis with Polyangiitis Drug Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2018-2034
3.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2018-2024
3.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2024-2034
3.4 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.4.1 North America Granulomatosis with Polyangiitis Drug Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2034)
3.4.3 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.5.1 Europe Granulomatosis with Polyangiitis Drug Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2018-2034)
3.5.3 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2018-2034)
3.6.3 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.7.1 Latin America Granulomatosis with Polyangiitis Drug Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2034)
3.7.3 Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2018-2034)
3.8.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2018-2034)
4.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024)
4.1.2 Global Granulomatosis with Polyangiitis Drug Sales by Type (2024-2034)
4.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2018-2034)
4.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2034)
4.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2018-2024)
4.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2024-2034)
4.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Granulomatosis with Polyangiitis Drug Price by Type (2018-2034)
5 Segment by Application
5.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2018-2034)
5.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024)
5.1.2 Global Granulomatosis with Polyangiitis Drug Sales by Application (2024-2034)
5.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2018-2034)
5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2034)
5.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2018-2024)
5.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2024-2034)
5.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Bionovis SA
6.1.1 Bionovis SA Corporation Information
6.1.2 Bionovis SA Description and Business Overview
6.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
6.1.5 Bionovis SA Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 ChemoCentryx Inc
6.3.1 ChemoCentryx Inc Corporation Information
6.3.2 ChemoCentryx Inc Description and Business Overview
6.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
6.3.5 ChemoCentryx Inc Recent Developments/Updates
6.4 Coherus BioSciences Inc
6.4.1 Coherus BioSciences Inc Corporation Information
6.4.2 Coherus BioSciences Inc Description and Business Overview
6.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
6.4.5 Coherus BioSciences Inc Recent Developments/Updates
6.5 Genor BioPharma Co Ltd
6.5.1 Genor BioPharma Co Ltd Corporation Information
6.5.2 Genor BioPharma Co Ltd Description and Business Overview
6.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
6.5.5 Genor BioPharma Co Ltd Recent Developments/Updates
6.6 GlaxoSmithKline Plc
6.6.1 GlaxoSmithKline Plc Corporation Information
6.6.2 GlaxoSmithKline Plc Description and Business Overview
6.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
6.6.5 GlaxoSmithKline Plc Recent Developments/Updates
6.7 Iltoo Pharma
6.6.1 Iltoo Pharma Corporation Information
6.6.2 Iltoo Pharma Description and Business Overview
6.6.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
6.7.5 Iltoo Pharma Recent Developments/Updates
6.8 Panacea Biotec Ltd
6.8.1 Panacea Biotec Ltd Corporation Information
6.8.2 Panacea Biotec Ltd Description and Business Overview
6.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
6.8.5 Panacea Biotec Ltd Recent Developments/Updates
6.9 Sandoz International GmbH
6.9.1 Sandoz International GmbH Corporation Information
6.9.2 Sandoz International GmbH Description and Business Overview
6.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
6.9.5 Sandoz International GmbH Recent Developments/Updates
6.10 The International Biotechnology Center (IBC) Generium
6.10.1 The International Biotechnology Center (IBC) Generium Corporation Information
6.10.2 The International Biotechnology Center (IBC) Generium Description and Business Overview
6.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
6.10.5 The International Biotechnology Center (IBC) Generium Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Granulomatosis with Polyangiitis Drug Industry Chain Analysis
7.2 Granulomatosis with Polyangiitis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Granulomatosis with Polyangiitis Drug Production Mode & Process
7.4 Granulomatosis with Polyangiitis Drug Sales and Marketing
7.4.1 Granulomatosis with Polyangiitis Drug Sales Channels
7.4.2 Granulomatosis with Polyangiitis Drug Distributors
7.5 Granulomatosis with Polyangiitis Drug Customers
8 Granulomatosis with Polyangiitis Drug Market Dynamics
8.1 Granulomatosis with Polyangiitis Drug Industry Trends
8.2 Granulomatosis with Polyangiitis Drug Market Drivers
8.3 Granulomatosis with Polyangiitis Drug Market Challenges
8.4 Granulomatosis with Polyangiitis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Granulomatosis with Polyangiitis Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) of Key Manufacturers (2018-2024)
Table 5. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Granulomatosis with Polyangiitis Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Granulomatosis with Polyangiitis Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Product Type & Application
Table 12. Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Granulomatosis with Polyangiitis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (K Pcs)
Table 18. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2018-2024)
Table 19. Global Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 20. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2024-2034)
Table 21. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Granulomatosis with Polyangiitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 27. North America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 28. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 32. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 33. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (K Pcs)
Table 37. Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 38. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 42. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 43. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 47. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 48. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2018-2024)
Table 51. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2024-2034)
Table 52. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2018-2024)
Table 53. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2024-2034)
Table 54. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Type (2018-2024)
Table 59. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Type (2024-2034)
Table 60. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2018-2024)
Table 61. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2024-2034)
Table 62. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2018-2024)
Table 63. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2024-2034)
Table 64. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Granulomatosis with Polyangiitis Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Application (2018-2024)
Table 69. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Application (2024-2034)
Table 70. Bionovis SA Corporation Information
Table 71. Bionovis SA Description and Business Overview
Table 72. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 73. Bionovis SA Granulomatosis with Polyangiitis Drug Product
Table 74. Bionovis SA Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Corporation Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 78. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. ChemoCentryx Inc Corporation Information
Table 81. ChemoCentryx Inc Description and Business Overview
Table 82. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 83. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product
Table 84. ChemoCentryx Inc Recent Developments/Updates
Table 85. Coherus BioSciences Inc Corporation Information
Table 86. Coherus BioSciences Inc Description and Business Overview
Table 87. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 88. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product
Table 89. Coherus BioSciences Inc Recent Developments/Updates
Table 90. Genor BioPharma Co Ltd Corporation Information
Table 91. Genor BioPharma Co Ltd Description and Business Overview
Table 92. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 93. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product
Table 94. Genor BioPharma Co Ltd Recent Developments/Updates
Table 95. GlaxoSmithKline Plc Corporation Information
Table 96. GlaxoSmithKline Plc Description and Business Overview
Table 97. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 98. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product
Table 99. GlaxoSmithKline Plc Recent Developments/Updates
Table 100. Iltoo Pharma Corporation Information
Table 101. Iltoo Pharma Description and Business Overview
Table 102. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 103. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product
Table 104. Iltoo Pharma Recent Developments/Updates
Table 105. Panacea Biotec Ltd Corporation Information
Table 106. Panacea Biotec Ltd Description and Business Overview
Table 107. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 108. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product
Table 109. Panacea Biotec Ltd Recent Developments/Updates
Table 110. Sandoz International GmbH Corporation Information
Table 111. Sandoz International GmbH Description and Business Overview
Table 112. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product
Table 114. Sandoz International GmbH Recent Developments/Updates
Table 115. The International Biotechnology Center (IBC) Generium Corporation Information
Table 116. The International Biotechnology Center (IBC) Generium Description and Business Overview
Table 117. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product
Table 119. The International Biotechnology Center (IBC) Generium Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Granulomatosis with Polyangiitis Drug Distributors List
Table 123. Granulomatosis with Polyangiitis Drug Customers List
Table 124. Granulomatosis with Polyangiitis Drug Market Trends
Table 125. Granulomatosis with Polyangiitis Drug Market Drivers
Table 126. Granulomatosis with Polyangiitis Drug Market Challenges
Table 127. Granulomatosis with Polyangiitis Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Granulomatosis with Polyangiitis Drug
Figure 2. Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Granulomatosis with Polyangiitis Drug Market Share by Type in 2022 & 2034
Figure 4. Benralizumab Product Picture
Figure 5. Avacopan Product Picture
Figure 6. Rituximab Biosimilar Product Picture
Figure 7. Others Product Picture
Figure 8. Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Granulomatosis with Polyangiitis Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Granulomatosis with Polyangiitis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Granulomatosis with Polyangiitis Drug Market Size (2018-2034) & (US$ Million)
Figure 15. Global Granulomatosis with Polyangiitis Drug Sales (2018-2034) & (K Pcs)
Figure 16. Global Granulomatosis with Polyangiitis Drug Average Price (USD/Pcs) & (2018-2034)
Figure 17. Granulomatosis with Polyangiitis Drug Report Years Considered
Figure 18. Granulomatosis with Polyangiitis Drug Sales Share by Manufacturers in 2022
Figure 19. Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Granulomatosis with Polyangiitis Drug Players: Market Share by Revenue in 2022
Figure 21. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Granulomatosis with Polyangiitis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 23. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2018-2034)
Figure 24. North America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2018-2034)
Figure 25. U.S. Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Canada Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2018-2034)
Figure 28. Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2018-2034)
Figure 29. Germany Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. France Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. U.K. Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Italy Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Russia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Asia Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Region (2018-2034)
Figure 35. Asia Pacific Granulomatosis with Polyangiitis Drug Revenue Market Share by Region (2018-2034)
Figure 36. China Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Japan Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. South Korea Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. India Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Australia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Taiwan Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Indonesia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Thailand Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Malaysia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Philippines Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2018-2034)
Figure 47. Latin America Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2018-2034)
Figure 48. Mexico Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Brazil Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Argentina Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Middle East & Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2018-2034)
Figure 52. Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Country (2018-2034)
Figure 53. Turkey Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. Saudi Arabia Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. U.A.E Granulomatosis with Polyangiitis Drug Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Global Sales Market Share of Granulomatosis with Polyangiitis Drug by Type (2018-2034)
Figure 57. Global Revenue Market Share of Granulomatosis with Polyangiitis Drug by Type (2018-2034)
Figure 58. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Type (2018-2034)
Figure 59. Global Sales Market Share of Granulomatosis with Polyangiitis Drug by Application (2018-2034)
Figure 60. Global Revenue Market Share of Granulomatosis with Polyangiitis Drug by Application (2018-2034)
Figure 61. Global Granulomatosis with Polyangiitis Drug Price (USD/Pcs) by Application (2018-2034)
Figure 62. Granulomatosis with Polyangiitis Drug Value Chain
Figure 63. Granulomatosis with Polyangiitis Drug Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed